XOMA Royalty Corp

NASDAQ:XOMAUnited States

Nov 7, 2024

Show headlines and story abstract

• -- Earnings Flash (XOMA) XOMA CORPORATION Posts Q3 Revenue $7.2M, from 7:37AM ET on Thursday Nov 07, 2024 by MT Newswires

  7:37AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: XOMA
  07:37 AM EST, 11/07/2024 (MT Newswires) -- ...

• Press Release: XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones

  7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: XOMA

• XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities, from 7:30AM ET on Thursday Nov 07, 2024 by Dow Jones

  7:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: XOMA
  Royalty purchase agreement asset impairment 23,000 1,575 Gain on the acquisition of Kinnate (19,316) -- Change in fair value of contingent consideration under RPAs, AAAs, and CPPAs -- (75) Common stock contribution to 401(k) 118 123 Amortization of intangible assets -- 673 Depreciation 8 2 Accretion of long-term debt discount and debt issuance costs 996 -- Non-cash lease expense 45 115 Change in fair value of equity securities (624) 121 Change in fair value of available-for-sale debt securities classified as cash equivalents 104 -- Changes in assets and liabilities: Trade and other receivables, net (41) (42) Prepaid expenses and other assets (72) (202) Accounts payable and accrued liabilities (1,348) (554) Operating lease liabilities (185) (120) Unearned revenue recognized under units-of-revenue method (1,828) (1,575) ------- ------- Net cash used in operating activities (10,845) (14,231) ------- ------- Cash flows from investing activities: Net cash acquired in Kinnate acquisition 18,926 -- Payments of consideration under RPAs, AAAs, and CPPAs (37,000) (14,650) Receipts under RPAs, AAAs, and CPPAs 26,263 8,428 Purchase of property and equipment (17) -- Net cash provided by (used in) investing activities 8,172 (6,222) ------- ------- Cash flows from financing activities: Principal payments -- debt (6,902) -- Debt issuance costs and loan fees paid in connection with long-term debt (740) -- Payment of preferred stock dividends (4,104) (4,104) Repurchases of common stock (13) -- Proceeds from exercise of options and other share-based compensation 4,127 208 Taxes paid related to net share settlement of equity awards (2,429) (5) Net cash used in financing activities (10,061) (3,901) ------- ------- Net decrease in cash, cash equivalents, and restricted cash (12,734) (24,354) Cash, cash equivalents, and restricted cash as of the beginning of the period 159,550 57,826 Cash, cash equivalents, and restricted cash as of the end of the period $146,816 $ 33,472 ======= ======= Supplemental Cash Flow Information: Cash paid for interest $ 9,985 $ -- Right-of-use assets obtained in exchange for operating lease liabilities $ -- $ 85 Non-cash investing and financing activities: Estimated initial fair value of the Exarafenib milestone asset in Kinnate acquisition $ 2,922 $ -- Estimated initial fair value of the Exarafenib milestone contingent consideration in Kinnate acquisition $ 2,922 $ -- Right-of-use assets obtained in exchange for operating lease liabilities in Kinnate acquisition $ 824 $ -- Relative fair value basis reduction of right-of-use assets in Kinnate acquisition $ (824) $ -- Accrual of contingent consideration under the Affitech CPPA $ 3,000 $ 3,000 Accrual of contingent consideration under the LadRx AAA $ 1,000 -- Estimated fair value of contingent consideration under the LadRx Agreements $ -- $ 1,000 Preferred stock dividend accrual $ 1,368 $ 1,368 Investor contact: Media contact: Juliane Snowden Kathy Vincent XOMA Royalty Corporation KV Consulting & Management +1-646-438-9754 +1-310-403-8951 juliane.snowden@xoma.com kathy@kathyvincent.com